ERYPRO IU

Main information

Trade name:
ERYPRO IU 1ML VIAL

Active ingredient:
Recombinant Human Erythropoietin

Available from:
Biocon

Dosage:
4000U/ML

Pharmaceutical form:
VIAL

Composition:
1ML

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

23-4-2018

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 32, Authorised

Europe - EMA - European Medicines Agency

23-4-2018

Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Revision: 5, Authorised

Europe - EMA - European Medicines Agency

20-4-2018

Human medicines European public assessment report (EPAR): Vemlidy, tenofovir alafenamide, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

20-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): Flublok, Trivalent, seasonal, recombinant influenza hemagglutinin vaccine, Therapeutic area: Vaccines/Infectious diseases

Europe - EFSA - European Food Safety Authority EFSA Journal

20-4-2018

Human medicines European public assessment report (EPAR): Xeloda, capecitabine, Revision: 23, Authorised

Europe - EMA - European Medicines Agency

20-4-2018

Veterinary medicine European public assessment report (EPAR): Suvaxyn Circo, porcine circovirus vaccine (inactivated, recombinant), Revision: 0, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, Revision: 11, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Ziagen, abacavir, Revision: 35, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Celsentri, maraviroc, Revision: 21, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Nimenrix, meningococcal group A, C, W 135 and Y conjugate vaccine, Revision: 22, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Revision: 11, Authorised

Europe - EMA - European Medicines Agency

19-4-2018

Human medicines European public assessment report (EPAR): Memantine ratiopharm, memantine, Revision: 5, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Fuzeon, enfuvirtide, Revision: 19, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Revision: 28, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Ritemvia, rituximab, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Revision: 2, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Recombinant human epidermal growth factor, Therapeutic area: Endocrinology, -gynacology-fertility-metabolism

Europe - EFSA - European Food Safety Authority EFSA Journal

18-4-2018

Human medicines European public assessment report (EPAR): Truxima, rituximab, Revision: 5, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Rituzena (previously Tuxella), rituximab, Revision: 4, Authorised

Europe - EMA - European Medicines Agency

18-4-2018

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

17-4-2018

Human medicines European public assessment report (EPAR): Bosulif, bosutinib, Revision: 13, Authorised

Europe - EMA - European Medicines Agency

17-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): Bexsero, Recombinant Neisseria meningitidis group B NHBA fusion protein / recombinant Neisseria meningitidis group B NadA protein / recombinant Neisseria meningitidis group B fHbp fusion protei

Europe - EFSA - European Food Safety Authority EFSA Journal

17-4-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Recombinant Clostridium difficile toxoid A / recombinant Clostridium difficile toxoid B, Therapeutic area: Vaccines

Europe - EFSA - European Food Safety Authority EFSA Journal

16-4-2018

Human medicines European public assessment report (EPAR): Simponi, golimumab, Revision: 29, Authorised

Europe - EMA - European Medicines Agency

16-4-2018

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Revision: 4, Authorised

Europe - EMA - European Medicines Agency

16-4-2018

Human medicines European public assessment report (EPAR): Respreeza, human alpha1-proteinase inhibitor, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

16-4-2018

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Revision: 32, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Aldara, imiquimod, Revision: 23, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Revision: 2, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Revision: 22, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Marixino (previously Maruxa), memantine, Revision: 6, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Potactasol, topotecan, Revision: 6, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Revision: 4, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Ravicti,  glycerol phenylbutyrate, Revision: 6, Authorised

Europe - EMA - European Medicines Agency

13-4-2018

Human medicines European public assessment report (EPAR): Latuda, lurasidone, Revision: 13, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, Revision: 20, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Torisel, temsirolimus, Revision: 27, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Zelboraf, vemurafenib, Revision: 17, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Cinryze, C1 inhibitor (human), Revision: 16, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Zydelig, idelalisib, Revision: 12, Authorised

Europe - EMA - European Medicines Agency

12-4-2018

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Revision: 12, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Revision: 1, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Teysuno, tegafur / gimeracil / oteracil, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Revision: 13, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Revision: 1, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Constella, linaclotide, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group-B vaccine (rDNA, component, adsorbed), Revision: 17, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Evotaz, atazanavir / cobicistat, Revision: 6, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Revision: 33, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Orphan designation: Adenovirus-associated viral vector serotype 8 containing the human RPGR gene, for the: Treatment of retinitis pigmentosa

Europe - EMA - European Medicines Agency

11-4-2018

Orphan designation: Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2, for the: Treatment of primary IgA nephropathy

Europe - EMA - European Medicines Agency

11-4-2018

Orphan designation: Human monoclonal IgG2 antibody against tissue factor pathway inhibitor, for the: Treatment of haemophilia A

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Bondronat, ibandronic acid, Revision: 25, Authorised

Europe - EMA - European Medicines Agency

11-4-2018

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Revision: 23, Authorised

Europe - EMA - European Medicines Agency

20-4-2018

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) - updated on RxList

US - RxList

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)

EU/3/18/2008 (Active substance: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1) - Orphan designation - Commission Decision (2018)2404 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/254/17

Europe -DG Health and Food Safety

18-4-2018

HYPERRHO S/D FULL DOSE (Rho(D) Immune Globulin (Human)) Solution [GRIFOLS USA, LLC]

Updated Date: Apr 18, 2018 EST

US - DailyMed

18-4-2018

HYPERRAB (Rabies Immune Globulin (Human)) Injection, Solution [GRIFOLS USA, LLC]

Updated Date: Apr 18, 2018 EST

US - DailyMed

16-4-2018

FDA Recognition of Public Human Genetic Variant Databases https://go.usa.gov/xQjp5 #MedicalDevice #PrecisionMedicine

FDA - U.S. Food and Drug Administration

16-4-2018

Actrapid (Novo Nordisk A/S)

Actrapid (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)2301 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

12-4-2018

Eyebrow-Raising Finding on How Human Communication Evolved

Title: Eyebrow-Raising Finding on How Human Communication EvolvedCategory: Health NewsCreated: 4/10/2018 12:00:00 AMLast Editorial Review: 4/11/2018 12:00:00 AM

US - MedicineNet

11-4-2018

Human Cancer Meds Might Help Save Tasmanian Devils

Title: Human Cancer Meds Might Help Save Tasmanian DevilsCategory: Health NewsCreated: 4/10/2018 12:00:00 AMLast Editorial Review: 4/10/2018 12:00:00 AM

US - MedicineNet

11-4-2018

Glassia ( Alpha1 Proteinase Inhibitor (Human) for Intravenous Administration) - updated on RxList

US - RxList